Puma Biotechnology, Inc.
HealthcareNASDAQ:PBYI · NASDAQ Global Select
+$0.10 today
Vol 0.26M · Avg 0.26M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$227.2M of revenue converted into $24.4M of net income for the selected period. Gross margin is 75.1% and net margin is 9.2%, showing how much revenue survives after costs and taxes. EPS is $0.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $228.4M -0.9% | $230.5M -2.2% | $235.6M +3.3% | $228.0M -9.9% | $253.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $58.2M -9.7% | $64.4M +2.7% | $62.7M +13.8% | $55.1M -13.5% | $63.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $170.2M +2.5% | $166.1M -4.0% | $173.0M +0.0% | $172.9M -8.7% | $189.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 74.5% +2.5pp | 72.1% -1.3pp | 73.4% -2.4pp | 75.8% +1.0pp | 74.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $62.1M +13.0% | $54.9M +9.0% | $50.4M -3.6% | $52.2M -27.3% | $71.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $71.2M -11.2% | $80.2M -10.2% | $89.3M -0.7% | $90.0M -22.6% | $116.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $132.9M -1.6% | $135.1M -3.7% | $140.3M -6.0% | $149.2M -20.7% | $188.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $10.9M -5.1% | $11.5M +0.0% | $11.5M +17.1% | $9.8M -13.0% | $11.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $53.3M +11.0% | $48.1M +1.2% | $47.5M +117.1% | $21.9M +566.7% | -$4.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 23.4% +2.5pp | 20.9% +0.7pp | 20.2% +10.6pp | 9.6% +11.5pp | -1.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $37.3M +20.5% | $31.0M -5.1% | $32.6M +37.6% | $23.7M +1738.8% | $1.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.3% +2.9pp | 13.4% -0.4pp | 13.9% +3.4pp | 10.4% +9.9pp | 0.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.1M -13.7% | $4.7M +81.3% | $2.6M +220.4% | $813.0K +408.1% | $160.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $6.6M -46.8% | $12.5M -6.6% | $13.3M +15.0% | $11.6M -9.5% | $12.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.5M +77.9% | -$6.9M +31.1% | -$10.0M +57.2% | -$23.3M +22.7% | -$30.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $35.8M +48.5% | $24.1M +6.3% | $22.7M +4861.5% | $457.0K +101.6% | -$28.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 15.7% +5.2pp | 10.5% +0.8pp | 9.6% +9.4pp | 0.2% +11.6pp | -11.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $4.7M +175.6% | -$6.2M -670.5% | $1.1M +138.0% | $455.0K +40.4% | $324.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $31.1M +2.8% | $30.3M +40.2% | $21.6M +1079450.0% | $2.0K +100.0% | -$29.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 13.6% +0.5pp | 13.1% +4.0pp | 9.2% +9.2pp | 0.0% +11.5pp | -11.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +0.0% | $1 +34.8% | $0 +2154.9% | $0 +102.8% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 -1.6% | $1 +37.8% | $0 +2116.7% | $0 +102.8% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $50.0M +2.8% | $48.6M +3.2% | $47.1M +5.5% | $44.7M +9.9% | $40.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $50.7M +3.2% | $49.1M +3.3% | $47.6M +5.8% | $44.9M +10.6% | $40.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Abeona Therapeutics Inc.
NASDAQ:ABEO
$315.18M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
$214.02M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PBYI generate?
Puma Biotechnology, Inc. (PBYI) reported $228.37M of revenue in fiscal 2025.
Is PBYI profitable?
Puma Biotechnology, Inc. (PBYI) reported $31.11M of net income, with a net margin of 13.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.